{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:05:12Z","timestamp":1776121512514,"version":"3.50.1"},"reference-count":64,"publisher":"JLE","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.nephro.2018.02.015","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:31:02Z","timestamp":1522337462000},"page":"S103-S113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Toxicit\u00e9 r\u00e9nale du m\u00e9thotrexate \u00e0 haute dose"],"prefix":"10.1684","volume":"14","author":[{"given":"Hugo","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Broutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2018.02.015_bib0325","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2018.02.015_bib0330","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncprheum0380","article-title":"Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs\u2014from bench to bedside","volume":"3","author":"Van der Heijden","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0335","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0340","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12185-013-1464-z","article-title":"Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy","volume":"98","author":"Yanagimachi","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-013-2319-2","article-title":"Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies","volume":"73","author":"Xu","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0350","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.282.6264.600","article-title":"Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation","volume":"282","author":"Woods","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.nephro.2018.02.015_bib0355","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0360","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0365","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-008-0772-0","article-title":"Renal dysfunction during and after high-dose methotrexate","volume":"63","author":"Green","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0370","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nephro.2018.02.015_bib0375","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0380","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.02.015_bib0385","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate","volume":"57","author":"Jacobs","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2018.02.015_bib0390","first-page":"695","article-title":"Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma","volume":"61","author":"Pitman","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.nephro.2018.02.015_bib0395","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2011.97","article-title":"Methotrexate in the urine","volume":"80","author":"Mallipattu","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.015_bib0400","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-0142(196901)23:1<126::AID-CNCR2820230115>3.0.CO;2-#","article-title":"Renal toxicity of methotrexate","volume":"23","author":"Condit","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0405","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pbc.20471","article-title":"Methotrexate induces cell swelling and necrosis in renal tubular cells","volume":"46","author":"Gr\u00f6nroos","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0410","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ndt\/gft248","article-title":"Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease","volume":"29","author":"Mulay","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.015_bib0415","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI63679","article-title":"Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1\u03b2 secretion","volume":"123","author":"Mulay","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2018.02.015_bib0420","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/1097-0142(19821215)50:12<2775::AID-CNCR2820501214>3.0.CO;2-E","article-title":"The effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration","volume":"50","author":"Freeman-Narrod","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0425","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/pbc.25137","article-title":"Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia: effect of HD-methotrexate on renal function","volume":"61","author":"Ylinen","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0430","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00467-015-3178-3","article-title":"Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study","volume":"30","author":"Carvalho Pedrosa","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0435","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.015_bib0440","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/pbc.21650","article-title":"Long-term follow-up of renal function after high-dose methotrexate treatment in children","volume":"51","author":"Gr\u00f6nroos","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0445","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1055-9965.EPI-13-0036","article-title":"Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study","volume":"22","author":"Mulder","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.nephro.2018.02.015_bib0450","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.1991.9.10.1766","article-title":"Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study","volume":"9","author":"Saeter","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0455","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","article-title":"High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients: high dose methotrexate toxicity in osteosarcoma patients","volume":"73","author":"Holmboe","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0460","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divine","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0465","first-page":"193","article-title":"[Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma]","volume":"48","author":"Ridolfi","year":"1996","journal-title":"Minerva Pediatr"},{"key":"10.1016\/j.nephro.2018.02.015_bib0470","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5045\/br.2016.51.1.50","article-title":"Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma","volume":"51","author":"Park","year":"2016","journal-title":"Blood Res"},{"key":"10.1016\/j.nephro.2018.02.015_bib0475","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia","volume":"57","author":"Lopez-Lopez","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0480","series-title":"Th\u00e9rapeutique dermatologique","first-page":"1096","article-title":"M\u00e9thotrexate","author":"Bournerias","year":"2001"},{"key":"10.1016\/j.nephro.2018.02.015_bib0485","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1470-2045(10)70062-0","article-title":"Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects","volume":"11","author":"Janeway","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0490","first-page":"1263","article-title":"Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate","volume":"26","author":"Reddick","year":"2005","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0495","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"21","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2018.02.015_bib0500","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1078155213482602","article-title":"High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity","volume":"20","author":"Chan","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nephro.2018.02.015_bib0505","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/1060028016661572","article-title":"Methotrexate elimination when coadministered with levetiracetam","volume":"50","author":"Reeves","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nephro.2018.02.015_bib0510","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2018.02.015_bib0515","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0520","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","article-title":"The effect of malignant effusions on methotrexate disposition","volume":"50","author":"Li","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0525","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","article-title":"Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients","volume":"62","author":"Joerger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0530","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Coadministration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0535","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nephro.2018.02.015_bib0540","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.phrs.2016.05.021","article-title":"Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance","volume":"118","author":"Muhrez","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nephro.2018.02.015_bib0545","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bcp.12326","article-title":"Urinary coproporphyrin I\/(I+III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance: urinary coproporphyrin I\/(I+III) ratio and transporter-mediated MTX clearance","volume":"78","author":"Benz-de Bretagne","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0550","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2125.2010.03744.x","article-title":"Cola beverage and delayed elimination of methotrexate: Cola beverage and delayed elimination of methotrexate","volume":"70","author":"Santucci","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0555","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/10428194.2012.737918","article-title":"Delayed elimination of methotrexate by cola beverages in a pediatric acute lymphoblastic leukemia population","volume":"54","author":"Bauters","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nephro.2018.02.015_bib0560","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.102.034330","article-title":"Characterization of methotrexate transport and its drug interactions with human organic anion transporters","volume":"302","author":"Takeda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nephro.2018.02.015_bib0565","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0570","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-199310000-00004","article-title":"Pharmacokinetic interaction between high-dose methotrexate and amoxycillin","volume":"15","author":"Ronchera","year":"1993","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.nephro.2018.02.015_bib0575","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","article-title":"Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nephro.2018.02.015_bib0580","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1124\/dmd.114.058529","article-title":"Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3","volume":"42","author":"Chioukh","year":"2014","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.nephro.2018.02.015_bib0585","first-page":"745","article-title":"Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration","volume":"61","author":"Von Hoff","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.nephro.2018.02.015_bib0590","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.015_bib0595","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF00548590","article-title":"Effect of urine pH and flow on renal clearance of methotrexate","volume":"19","author":"Sand","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0600","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00280-010-1259-3","article-title":"Hyper-alkalinization without hyperhydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma","volume":"66","author":"Mir","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0605","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/1097-0142(19890315)63:6+<995::AID-CNCR2820631302>3.0.CO;2-R","article-title":"New vistas for leucovorin in cancer chemotherapy","volume":"63","author":"Bleyer","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2018.02.015_bib0610","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-87-4-495_2","article-title":"Methotrexate and hemodialysis","volume":"87","author":"Hande","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2018.02.015_bib0615","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.02.015_bib0620","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/ckj\/sfu093","article-title":"Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase","volume":"7","author":"Connors","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2018.02.015_bib0625","first-page":"1824","article-title":"Thymidine requirements for the rescue of patients treated with high-dose methotrexate","volume":"40","author":"Howell","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.nephro.2018.02.015_bib0630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt197926163","article-title":"Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate","volume":"26","author":"Donehower","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nephro.2018.02.015_bib0635","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.1992.10.8.1359","article-title":"Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys","volume":"10","author":"Adamson","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2018.02.015_bib0640","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.02.015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:12:46Z","timestamp":1741191166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518300300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":64,"alternative-id":["S1769725518300300"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.015","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 r\u00e9nale du m\u00e9thotrexate \u00e0 haute dose","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}